A 21st-century remedy for missed meds
Missing crucial doses of medicines and vaccines could become a thing of the past thanks to Rice University bioengineers’ next-level technology for making time-released drugs. “This is a… read more.
Missing crucial doses of medicines and vaccines could become a thing of the past thanks to Rice University bioengineers’ next-level technology for making time-released drugs. “This is a… read more.
Researchers report that patients who knowingly took a “sugar pill” placebo along with daily methadone treatment achieved significantly higher 90-day adherence to treatment for opioid abuse disorder than… read more.
The European Medicines Agency (EMA) approved a total of 89 new medicines in 2022. Of these, 41 had a new active substance which had never been authorised in… read more.
The European Medicines Agency (EMA) has launched a pilot to give scientific advice on the intended clinical development of certain high-risk medical devices. The new initiative applies to… read more.
European countries experienced significant shortages of medicines as seasonal illnesses spread across the continent. Now authorities at EU level are working to avoid a repeat of the problem,… read more.
Important information about cancer drug benefits, and related uncertainties, is frequently omitted from official prescription drug information sources for clinicians and patients in Europe, finds an analysis published… read more.
New research has revealed important information about how aspirin works. Even though this drug has been available commercially since the late 1800s, scientists have not yet fully elucidated… read more.
A new study from researchers from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, has shed new light on the best strategies… read more.
A team of researchers from Aston University has developed a new technique that could be a game changer for the medical and drinks industries. The technology enables insoluble… read more.
A Kaiser Permanente study confirms the benefit of nirmatrelvir-ritonavir, also known as Paxlovid, as an early-stage treatment to prevent hospitalization for people with mild to moderate COVID-19, regardless… read more.
Two phase 3 trials suggest that a 16 week treatment with a drug called lebrikizumab was effective in adults and adolescents with moderate to severe dermatitis, according to… read more.
Patients with ‘blinding’ headaches known as Idiopathic Intercranial Hypertension (IIH) could be treated with an injectable peptide used for type 2 diabetes, a new trial has found. The… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.